Q4 Earnings Announcements…
That’s right… Q4 earnings announcements are coming… And these five microcap stocks appear to be in an excellent position to see a surge in share price.
>>> Click here to see all 5 stocks
pixel

ORPH Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £51,020.40
Insider Selling (Last 12 Months): GBX 0

Open Orphan Insider Trading History Chart

This chart shows the insider buying and selling history at Open Orphan by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Open Orphan Share Price & Price History

Current Price: GBX 10
Price Change: Price Increase of +0.5 (5.26%)
As of 10/25/2022 10:36 PM ET

This chart shows the closing price history over time for ORPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel

Open Orphan Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2022Yamin Mo' KhanInsiderBuy510,204GBX 10£51,020.40
7/14/2021Cathal FrielInsiderBuy1,132,075GBX 26£294,339.50
See Full Table
Next-Generation Fighter Jets?!? (Must See)
The U.S. Department of Defense is using one shocking company to develop breakthrough tech...And at less than $2... this could be the last bargain on the market.

Get the Details Here (Act Fast... a Key Announcement in December Could Send It Rocketing)
>>>
pixel

SEC Filings (Institutional Ownership Changes) for Open Orphan (LON:ORPH)

Open Orphan logo
Open Orphan Plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.
Read More on Open Orphan

Today's Range

Now: GBX 10
Low: 9.50
High: 10.38

50 Day Range

MA: GBX 9.85
Low: 8.75
High: 10.50

52 Week Range

Now: GBX 10
Low: 8.68
High: 25

Volume

652,639 shs

Average Volume

1,559,247 shs

Market Capitalization

£67.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Open Orphan?

Open Orphan's top insider shareholders include:
  1. Cathal Friel (Insider)
  2. Yamin Mo' Khan (Insider)
Learn More about top insider investors at Open Orphan.
Q4 Earnings Announcements…
That’s right… Q4 earnings announcements are coming… And these five microcap stocks appear to be in an excellent position to see a surge in share price.
>>> Click here to see all 5 stocks
pixel